T1	CHEM 44 55	Rivaroxabán
#1	AnnotatorNotes T1	C1739768; rivaroxaban; Organic Chemical · Pharmacologic Substance
T2	PROC 904 912	tratados
#2	AnnotatorNotes T2	C0087111; Therapeutic procedure; Therapeutic or Preventive Procedure
T3	CHEM 75 86	rivaroxabán
#3	AnnotatorNotes T3	C1739768; rivaroxaban; Organic Chemical · Pharmacologic Substance
T4	CHEM 118 126	Aspirina
#4	AnnotatorNotes T4	C0004057; aspirin; Organic Chemical · Pharmacologic Substance
T5	PROC 133 143	prevención
#5	AnnotatorNotes T5	C0199176; Prophylactic treatment; Therapeutic or Preventive Procedure
T6	DISO 161 179	coágulos de sangre
#6	AnnotatorNotes T6	C0087086; Thrombus; Pathologic Function | C0302148; Blood Clot; Pathologic Function
T7	ANAT 198 204	pierna
#7	AnnotatorNotes T7	C1140621; Leg; Body Part, Organ, or Organ Component | C1269079; Entire lower limb; Body Part, Organ, or Organ Component
T8	ANAT 207 215	pulmones
#8	AnnotatorNotes T8	C0024109; Lung; Body Part, Organ, or Organ Component | C1278908; Entire lung; Body Part, Organ, or Organ Component
T9	CHEM 237 248	Rivaroxabán
#9	AnnotatorNotes T9	C1739768; rivaroxaban; Organic Chemical · Pharmacologic Substance
T10	CHEM 268 279	rivaroxabán
#10	AnnotatorNotes T10	C1739768; rivaroxaban; Organic Chemical · Pharmacologic Substance
T11	CHEM 306 309	AAS
#11	AnnotatorNotes T11	C0004057; aspirin; Organic Chemical · Pharmacologic Substance
T12	PROC 316 326	prevención
#12	AnnotatorNotes T12	C0199176; Prophylactic treatment; Therapeutic or Preventive Procedure
T13	DISO 345 379	tromboembolismo venoso sintomático
T14	DISO 408 445	trombosis venosa profunda sintomática
T15	DISO 450 466	embolia pulmonar
#13	AnnotatorNotes T15	C0034065; Pulmonary Embolism; Pathologic Function
T16	PROC 515 525	Prevención
#14	AnnotatorNotes T16	C0199176; Prophylactic treatment; Therapeutic or Preventive Procedure
T17	DISO 529 547	coágulos de sangre
#15	AnnotatorNotes T17	C0087086; Thrombus; Pathologic Function | C0302148; Blood Clot; Pathologic Function
T18	ANAT 570 575	venas
#16	AnnotatorNotes T18	C0042449; Veins; Body Part, Organ, or Organ Component | C1278960; Entire vein; Body Part, Organ, or Organ Component
T19	ANAT 583 590	piernas
#17	AnnotatorNotes T19	C1140621; Leg; Body Part, Organ, or Organ Component | C1269079; Entire lower limb; Body Part, Organ, or Organ Component
T20	ANAT 597 613	vasos sanguíneos
#18	AnnotatorNotes T20	C0005847; Blood Vessel; Body Part, Organ, or Organ Component | C1283786; Entire blood vessel; Body Part, Organ, or Organ Component
T21	PROC 655 665	Prevención
#19	AnnotatorNotes T21	C0199176; Prophylactic treatment; Therapeutic or Preventive Procedure
T22	DISO 684 724	tromboembolismo venoso (TEV) sintomático
T23	DISO 753 790	trombosis venosa profunda sintomática
T24	DISO 795 811	embolia pulmonar
#20	AnnotatorNotes T24	C0034065; Pulmonary Embolism; Pathologic Function
T25	DISO 855 857	EP
#21	AnnotatorNotes T25	C0034065; Pulmonary Embolism; Pathologic Function
T26	DISO 862 877	TVP sintomática
T27	ANAT 621 629	pulmones
#22	AnnotatorNotes T27	C0024109; Lung; Body Part, Organ, or Organ Component | C1278908; Entire lung; Body Part, Organ, or Organ Component
T28	PROC 994 1026	Consentimiento informado escrito
#23	AnnotatorNotes T28	C0811741; Obtain informed written consent; Health Care Activity
T29	CHEM 1142 1157	anticoagulantes
#24	AnnotatorNotes T29	C0003280; Anticoagulants; Pharmacologic Substance
T30	DISO 1182 1199	Hipersensibilidad
#25	AnnotatorNotes T30	C0020517; Hypersensitivity; Pathologic Function | C0429891; Hypersensitivity finding; Finding
T31	PROC 1203 1231	tratamiento en investigación
#26	AnnotatorNotes T31	C0949266; Therapies, Investigational; Therapeutic or Preventive Procedure
T32	PROC 1320 1348	tratamiento en investigación
#27	AnnotatorNotes T32	C0949266; Therapies, Investigational; Therapeutic or Preventive Procedure
T33	PROC 1383 1410	tratamiento antiplaquetario
T34	CHEM 1413 1451	fármaco antiinflamatorio no esteroideo
#28	AnnotatorNotes T34	C0003211; Anti-Inflammatory Agents, Non-Steroidal; Pharmacologic Substance
T35	CHEM 1466 1470	AINE
#29	AnnotatorNotes T35	C0003211; Anti-Inflammatory Agents, Non-Steroidal; Pharmacologic Substance
T36	DISO 1475 1494	Enfermedad hepática
#30	AnnotatorNotes T36	C0023895; Liver diseases; Disease or Syndrome
T37	DISO 1506 1518	coagulopatía
#31	AnnotatorNotes T37	C0005779; Blood Coagulation Disorders; Disease or Syndrome
T38	DISO 1545 1555	hemorragia
#32	AnnotatorNotes T38	C0019080; Hemorrhage; Pathologic Function
T39	PROC 1583 1609	Aclaramiento de creatinina
#33	AnnotatorNotes T39	C0373595; Creatinine clearance measurement; Laboratory Procedure
T40	DISO 1636 1646	Hemorragia
#34	AnnotatorNotes T40	C0019080; Hemorrhage; Pathologic Function
T41	DISO 1674 1684	hemorragia
#35	AnnotatorNotes T41	C0019080; Hemorrhage; Pathologic Function
T42	PROC 1706 1728	terapia anticoagulante
#36	AnnotatorNotes T42	C0150457; Anticoagulant therapy; Therapeutic or Preventive Procedure
T43	CHEM 1784 1873	inhibidores potentes de la isoenzima del citocromo P450 3A4 (CYP3A4) y la glucoproteína P
T44	CHEM 1875 1879	gp-P
T45	CHEM 1902 1969	inhibidores de la proteasa del virus de la inmunodeficiencia humana
#37	AnnotatorNotes T45	C0162714; HIV Protease Inhibitors; Pharmacologic Substance
T46	CHEM 1987 2015	agentes antimicóticos azoles
#38	AnnotatorNotes T46	C0360363; Azole antifungal; Organic Chemical · Pharmacologic Substance
T47	CHEM 2017 2028	ketoconazol
#39	AnnotatorNotes T47	C0022625; ketoconazole; Organic Chemical · Pharmacologic Substance
T48	CHEM 2030 2041	itraconazol
#40	AnnotatorNotes T48	C0064113; itraconazole; Organic Chemical · Pharmacologic Substance
T49	CHEM 2043 2054	voriconazol
#41	AnnotatorNotes T49	C0393080; voriconazole; Organic Chemical · Pharmacologic Substance
T50	CHEM 2057 2068	posaconazol
#42	AnnotatorNotes T50	C0936148; posaconazole; Organic Chemical · Pharmacologic Substance
T51	PROC 2149 2172	medidas anticonceptivas
T52	PROC 2345 2359	aleatorización
#43	AnnotatorNotes T52	C0034656; Randomization; Research Activity
T53	ANAT 173 179	sangre
#44	AnnotatorNotes T53	C0005767; Blood; Body Substance
T54	ANAT 361 367	venoso
#45	AnnotatorNotes T54	C0042449; Veins; Body Part, Organ, or Organ Component | C1278960; Entire vein; Body Part, Organ, or Organ Component
T55	ANAT 418 424	venosa
#46	AnnotatorNotes T55	C0042449; Veins; Body Part, Organ, or Organ Component | C1278960; Entire vein; Body Part, Organ, or Organ Component
T56	ANAT 458 466	pulmonar
#47	AnnotatorNotes T56	C0034052; Pulmonary artery structure; Body Part, Organ, or Organ Component | C1269026; Entire pulmonary artery; Body Part, Organ, or Organ Component
T57	ANAT 541 547	sangre
#48	AnnotatorNotes T57	C0005767; Blood; Body Substance
T58	ANAT 700 706	venoso
#49	AnnotatorNotes T58	C0042449; Veins; Body Part, Organ, or Organ Component | C1278960; Entire vein; Body Part, Organ, or Organ Component
T59	ANAT 763 769	venosa
#50	AnnotatorNotes T59	C0042449; Veins; Body Part, Organ, or Organ Component | C1278960; Entire vein; Body Part, Organ, or Organ Component
T60	ANAT 803 811	pulmonar
#51	AnnotatorNotes T60	C0034052; Pulmonary artery structure; Body Part, Organ, or Organ Component | C1269026; Entire pulmonary artery; Body Part, Organ, or Organ Component
T62	CHEM 1395 1410	antiplaquetario
#52	AnnotatorNotes T62	C0085826; Antiplatelet Agents; Pharmacologic Substance
T63	ANAT 1486 1494	hepática
#53	AnnotatorNotes T63	C0023884; Liver; Body Part, Organ, or Organ Component | C1278929; Entire liver; Body Part, Organ, or Organ Component
T64	CHEM 1599 1609	creatinina
#54	AnnotatorNotes T64	C0010294; creatinine; Biologically Active Substance · Organic Chemical
T65	CHEM 1714 1728	anticoagulante
#55	AnnotatorNotes T65	C0003280; Anticoagulants; Pharmacologic Substance
T66	CHEM 2258 2265	fármaco
#56	AnnotatorNotes T66	C0013227; Pharmaceutical Preparations; Pharmacologic Substance | C0456386; Medicament; Pharmacologic Substance
T67	Date 12 16	2013
T68	Dose 58 72	dosis reducida
#57	AnnotatorNotes T68	C0445550; Low dose; Quantitative Concept
T69	Dose 89 103	dosis estándar
T70	Date 144 157	a largo plazo
T71	Dose 251 265	dosis reducida
#58	AnnotatorNotes T71	C0445550; Low dose; Quantitative Concept
T72	Dose 282 296	dosis estándar
T73	Date 327 340	a largo plazo
T74	LIVB 394 403	pacientes
#59	AnnotatorNotes T74	C0030705; Patients; Patient or Disabled Group
T75	Date 666 679	a largo plazo
T76	LIVB 739 748	pacientes
#60	AnnotatorNotes T76	C0030705; Patients; Patient or Disabled Group
T77	LIVB 841 850	Pacientes
#61	AnnotatorNotes T77	C0030705; Patients; Patient or Disabled Group
T78	Duration 913 928	de 6 a 12 meses
T79	Neg_cue 929 932	sin
T80	Neg_cue 1073 1075	no
T82	Spec_cue 1535 1544	riesgo de
T85	Spec_cue 1656 1662	riesgo
T86	Duration 1750 1759	< 6 meses
T87	LIVB 1933 1969	virus de la inmunodeficiencia humana
#62	AnnotatorNotes T87	C0019682; HIV; Virus
T89	LIVB 2107 2129	Mujeres en edad fértil
#63	AnnotatorNotes T89	C4324275; Woman of childbearing potential; Population Group
T90	Age 2118 2129	edad fértil
T92	Neg_cue 2134 2136	no
T93	PHYS 2195 2203	embarazo
#64	AnnotatorNotes T93	C0032961; Pregnancy; Organism Function
T94	PHYS 2209 2218	lactancia
#65	AnnotatorNotes T94	C0006147; Breast Feeding; Organism Function | C0022925; Lactation; Organ or Tissue Function
T96	Duration 2312 2328	los treinta días
T98	PROC 933 967	interrupción de la anticoagulación
#66	AnnotatorNotes T98	C0850893; stop medication; Therapeutic or Preventive Procedure + C0150457; Anticoagulant therapy; Therapeutic or Preventive Procedure
T99	Duration 968 989	superior a una semana
T100	Age 1087 1097	edad legal
T81	Dose 1160 1178	dosis terapéuticas
T83	CHEM 2268 2303	producto sanitario en investigación
#67	AnnotatorNotes T83	C0013230; Investigational New Drugs; Pharmacologic Substance (?)
A1	Assertion T98 Negated
A2	Assertion T100 Negated
A3	Assertion T38 Speculated
A4	Assertion T41 Speculated
A5	Assertion T89 Negated
A6	Assertion T51 Negated
A7	Status T30 History_of
A8	Assertion T32 Contraindicated
A9	Assertion T42 Contraindicated
A10	Assertion T65 Contraindicated
#68	AnnotatorNotes T70	C0443252; Long-term; Temporal Concept
#69	AnnotatorNotes T73	C0443252; Long-term; Temporal Concept
#70	AnnotatorNotes T75	C0443252; Long-term; Temporal Concept
#71	AnnotatorNotes T33	C1096021; Antiplatelet therapy; Therapeutic or Preventive Procedure
#72	AnnotatorNotes T51	C0700589; Contraceptive methods; Therapeutic or Preventive Procedure
T61	Quantifier_or_Qualifier 1441 1451	esteroideo
A11	Assertion T61 Negated
T84	Neg_cue 1438 1440	no
R1	Negation Arg1:T79 Arg2:T98	
R2	Has_Duration_or_Interval Arg1:T98 Arg2:T99	
R3	Negation Arg1:T80 Arg2:T100	
R4	Negation Arg1:T84 Arg2:T61	
R5	Speculation Arg1:T82 Arg2:T38	
T88	Quantifier_or_Qualifier 1556 1578	clínicamente relevante
A12	Assertion T88 Speculated
R6	Has_Quantifier_or_Qualifier Arg1:T38 Arg2:T88	
R7	Speculation Arg1:T85 Arg2:T41	
R8	Negation Arg1:T92 Arg2:T51	
T91	Route 2089 2102	vía sistémica
#73	AnnotatorNotes T91	C0205373; Systemic; Functional Concept (?)
R9	Has_Dose_or_Strength Arg1:T1 Arg2:T68	
R10	Has_Dose_or_Strength Arg1:T3 Arg2:T69	
R11	Used_for Arg1:T4 Arg2:T5	
R12	Used_for Arg1:T1 Arg2:T5	
R13	Used_for Arg1:T3 Arg2:T5	
R14	Overlap Arg1:T5 Arg2:T70	
R15	Before Arg1:T5 Arg2:T6	
R16	Location_of Arg1:T7 Arg2:T6	
R17	Location_of Arg1:T8 Arg2:T6	
R18	Has_Dose_or_Strength Arg1:T9 Arg2:T71	
R19	Has_Dose_or_Strength Arg1:T10 Arg2:T72	
R20	Used_for Arg1:T11 Arg2:T12	
R21	Used_for Arg1:T9 Arg2:T12	
R22	Used_for Arg1:T10 Arg2:T12	
R23	Overlap Arg1:T12 Arg2:T73	
R24	Location_of Arg1:T54 Arg2:T13	
R25	Experiences Arg1:T74 Arg2:T9	
R26	Experiences Arg1:T74 Arg2:T10	
R27	Experiences Arg1:T74 Arg2:T11	
R28	Experiences Arg1:T74 Arg2:T13	
R29	Experiences Arg1:T74 Arg2:T12	
R30	Experiences Arg1:T74 Arg2:T14	
R31	Experiences Arg1:T74 Arg2:T15	
R32	Location_of Arg1:T56 Arg2:T15	
R33	Location_of Arg1:T55 Arg2:T14	
T95	Observation 380 390	recurrente
#74	AnnotatorNotes T95	C2825055; Recurrence (disease attribute); Pathologic Function
R34	Has_Quantifier_or_Qualifier Arg1:T13 Arg2:T95	
R36	Before Arg1:T16 Arg2:T17	
R37	Location_of Arg1:T18 Arg2:T17	
R38	Location_of Arg1:T19 Arg2:T17	
R39	Location_of Arg1:T20 Arg2:T17	
R40	Location_of Arg1:T27 Arg2:T17	
R41	Overlap Arg1:T21 Arg2:T75	
R42	Before Arg1:T21 Arg2:T22	
R43	Location_of Arg1:T58 Arg2:T22	
T97	Observation 725 735	recurrente
#75	AnnotatorNotes T97	C2825055; Recurrence (disease attribute); Pathologic Function
R44	Has_Quantifier_or_Qualifier Arg1:T22 Arg2:T97	
R45	Experiences Arg1:T76 Arg2:T21	
R48	Experiences Arg1:T76 Arg2:T23	
R49	Location_of Arg1:T59 Arg2:T23	
R50	Location_of Arg1:T60 Arg2:T24	
R51	Experiences Arg1:T76 Arg2:T24	
R46	Before Arg1:T23 Arg2:T22	
R47	Before Arg1:T24 Arg2:T22	
R52	Experiences Arg1:T77 Arg2:T25	
R53	Experiences Arg1:T77 Arg2:T26	
R54	Has_Duration_or_Interval Arg1:T2 Arg2:T78	
R55	Experiences Arg1:T77 Arg2:T2	
R56	Experiences Arg1:T77 Arg2:T98	
R57	Has_Dose_or_Strength Arg1:T29 Arg2:T81	
R58	Causes Arg1:T31 Arg2:T30	
R59	Used_for Arg1:T62 Arg2:T33	
R60	Has_Quantifier_or_Qualifier Arg1:T34 Arg2:T61	
R61	Has_Quantifier_or_Qualifier Arg1:T35 Arg2:T61	
R62	Location_of Arg1:T63 Arg2:T36	
R63	Overlap Arg1:T36 Arg2:T37	
R64	Before Arg1:T36 Arg2:T38	
R65	Before Arg1:T37 Arg2:T38	
T101	Result_or_Value 1620 1631	< 30 ml/min
R66	Has_Result_or_Value Arg1:T39 Arg2:T101	
T102	Observation 1656 1673	riesgo elevado de
#76	AnnotatorNotes T102	C0332167; High risk of; Finding
R67	Before Arg1:T102 Arg2:T41	
R68	Used_for Arg1:T65 Arg2:T42	
T103	Quantifier_or_Qualifier 1647 1653	activa
#77	AnnotatorNotes T103	C0205177; Active; Qualitative Concept | C0679217; Active State; Idea or Concept
R69	Has_Quantifier_or_Qualifier Arg1:T40 Arg2:T103	
T104	CONC 1732 1749	Esperanza de vida
#78	AnnotatorNotes T104	C0023671; Life Expectancy; Group Attribute
R70	Has_Duration_or_Interval Arg1:T104 Arg2:T86	
T105	Quantifier_or_Qualifier 1768 1780	concomitante
#79	AnnotatorNotes T105	C0521115; Simultaneous; Temporal Concept
R71	Has_Quantifier_or_Qualifier Arg1:T43 Arg2:T105	
R72	Has_Quantifier_or_Qualifier Arg1:T45 Arg2:T105	
R73	Has_Quantifier_or_Qualifier Arg1:T46 Arg2:T105	
R74	Has_Quantifier_or_Qualifier Arg1:T47 Arg2:T105	
R75	Has_Quantifier_or_Qualifier Arg1:T48 Arg2:T105	
R76	Has_Quantifier_or_Qualifier Arg1:T49 Arg2:T105	
R77	Has_Quantifier_or_Qualifier Arg1:T50 Arg2:T105	
R78	Has_Route_or_Mode Arg1:T46 Arg2:T91	
R79	Has_Route_or_Mode Arg1:T47 Arg2:T91	
R80	Has_Route_or_Mode Arg1:T48 Arg2:T91	
R81	Has_Route_or_Mode Arg1:T49 Arg2:T91	
R82	Has_Route_or_Mode Arg1:T50 Arg2:T91	
R83	Has_Age Arg1:T89 Arg2:T90	
R84	Experiences Arg1:T89 Arg2:T51	
T106	Quantifier_or_Qualifier 2173 2182	adecuadas
A13	Assertion T106 Negated
#80	AnnotatorNotes T106	C0205411; Adequate; Qualitative Concept
R85	Has_Quantifier_or_Qualifier Arg1:T51 Arg2:T106	
R86	Negation Arg1:T92 Arg2:T106	
R87	Experiences Arg1:T89 Arg2:T93	
R88	Experiences Arg1:T89 Arg2:T94	
R89	Overlap Arg1:T51 Arg2:T93	
R90	Overlap Arg1:T51 Arg2:T94	
T107	Observation 2223 2250	Participación en un estudio
#81	AnnotatorNotes T107	C1278516; Patient participation status; Finding
R93	Overlap Arg1:T66 Arg2:T96	
R94	Overlap Arg1:T83 Arg2:T96	
R95	Before Arg1:T66 Arg2:T52	
R96	Before Arg1:T83 Arg2:T52	
R97	Before Arg1:T107 Arg2:T52	
#82	AnnotatorNotes T44	C0242643; P-Glycoprotein; Amino Acid, Peptide, or Protein · Biologically Active Substance
#83	AnnotatorNotes T88	C5209294; Clinical relevance; Intellectual Product
R98	Speculation Arg1:T82 Arg2:T88	
R35	Experiences Arg1:T76 Arg2:T22	
A14	Assertion T91 Hypothetical
A15	Experiencer T74 Patient
A16	Experiencer T76 Patient
A17	Experiencer T77 Patient
A18	Experiencer T89 Patient
